Orders from 120 EUR Free delivery from 250 EUR Ready for pickup dead drop: collect in 5 min Free parcel delivery from 250 EUR

Substances · Benzodiazepines and thienodiazepines

Bromazolam

C17H13BrN4 CAS 71368-80-4 Analytical reference material — not for human consumption
Bromazolam, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
Bromazolam
IUPAC name
8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Parent CAS number (reference)
71368-80-4
Molecular formula
C17H13BrN4
Molecular weight
353.2 g/mol
InChIKey
KCEIOBKDDQAYCM-UHFFFAOYSA-N
PubChem
CID 12562546
Source
PubChem
Verified synonyms & catalog abbreviations
XLI-269 8-Bromo-alprazolam

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Bromazolam

GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam) Triazolobenzodiazepine
Verified PubChem & CAS Identity C17H13BrN4 · CAS 71368-80-4 · CID 12562546
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 353.2 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Moderate-High
GABAₐ α₅ Amnestic / Cognitive Modulation Moderate

Non-selective high-affinity PAM across alpha1, alpha2, alpha3, and alpha5 GABA-A receptor subtypes (structurally the 8-bromo analogue of alprazolam).

Biotransformation & Active Metabolites

Hepatic CYP3A4 hydroxylation to alpha-hydroxybromazolam and 4-hydroxybromazolam followed by glucuronidation.

Temporal Pharmacokinetics

GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam) — 1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

  1. Onset 20–45 min
  2. Peak Window 1.5–3 h
  3. Total Window 6–10 h
  4. Residual / Half-Life 8–18 h residual sedation

1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
0.5 mg
Cognitive & Sensory

Subtle threshold receptor activity (GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
0.5–1 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
1–2 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
2–4 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
4–5+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

Physicochemical Stability & Storage

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Comprehensive Analytical & Toxicological Monograph

Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 71368-80-4, PubChem CID 12562546) is a triazolobenzodiazepine reference compound (C17H13BrN4, 353.2 g/mol) classified pharmacologically as a GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam). Non-selective high-affinity PAM across alpha1, alpha2, alpha3, and alpha5 GABA-A receptor subtypes (structurally the 8-bromo analogue of alprazolam). Hepatic CYP3A4 hydroxylation to alpha-hydroxybromazolam and 4-hydroxybromazolam followed by glucuronidation. In published observational and toxicological literature, threshold response is noted at 0.5 mg, light range at 0.5–1 mg, common reference range at 1–2 mg, strong intensity at 2–4 mg, and heavy/adverse territory at 4–5+ mg, with an onset of 20–45 min, peak window of 1.5–3 h, and total duration of 6–10 h (8–18 h residual sedation). 1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C17H13BrN4 and a molar mass of 353.2 g/mol. The parent molecule is indexed under CAS registry number 71368-80-4 and in the NCBI PubChem database as CID 12562546 (Standard InChIKey: KCEIOBKDDQAYCM-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Bromazolam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations